Ribociclib inhibited cell proliferation in the HCC cell models, downregulating p-CDK6 and p-Rb, while cyclin D1 levels were increased as shown for abemaciclib (Figures 3A, B). This evidence concerns the gene RB1 and hepatocellular carcinoma.